Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;30(9):7271-7280.
doi: 10.1007/s00520-022-07159-3. Epub 2022 May 21.

Risk factors for renal impairment in patients with hematological cancer receiving antineoplastic treatment

Priscila Nunes Costa Travassos  1 , Paulo Goberlânio de Barros Silva  2 , Milena Oliveira Freitas  3 , Marcus Davis Machado Braga  1 , Fernando Barroso Duarte  4 , Jéssica Karen de Oliveira Maia  4 , Helena Pitombeira  4 , Jacqueline Holanda de Sousa  4 , Ana Paula Negreiros Nunes Alves  1   5
Affiliations

Risk factors for renal impairment in patients with hematological cancer receiving antineoplastic treatment

Priscila Nunes Costa Travassos et al. Support Care Cancer. 2022 Sep.

Abstract

Purpose: Antineoplastic treatments, mainly chemotherapy, affect the kidneys, causing toxicity, and can trigger acute and chronic kidney injuries. This study aimed to analyze the prevalence of renal disorders in patients with oncohematological neoplasms receiving antineoplastic treatment.

Methods: This retrospective cohort study included 75 patients with hematological cancer who underwent chemotherapy between 2012 and 2018 in the Hematology Sector of the Walter Cantídeo University Hospital of the Federal University of Ceará. Sociodemographic and clinical data, blood biochemical assessment findings, and glomerular filtration rate (GFR) were analyzed using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. The data were tabulated; transferred to the Statistical Package for the Social Sciences software, version 20.0; and analyzed using Pearson's chi-square test or Fisher's exact test for categorical variables followed by a multinomial logistic regression model (p < 0.05).

Results: The prevalence of renal disorders was 52.4% according to the CKD-EPI equation for GFR events. There was a significant association between the decrease in GFRs and the following variables: female sex (p = 0.002), diagnosis of multiple myeloma (p = 0.008), start of treatment within 40 days (p = 0.005), and the following antineoplastic treatments: cyclophosphamide, vincristine, and prednisone (p = 0.026); irarubicin (p = 0.032); azacytidine, dexamethasone, and cyclophosphamide (p < 0.001); zoledronic acid (p < 0.001); and pamidronate (p = 0.012). CALGB 8811 (p < 0.001) was inversely associated with a reduction in the GFR.

Conclusions: The prevalence of renal disorders was high in patients with oncohematological neoplasms receiving antineoplastic treatment. This requires periodic monitoring of the evaluation of renal function since reductions in GFRs were significantly associated with different treatment protocols used.

Keywords: Chemotherapy; Glomerular filtration rate; Leukemia; Lymphoma; Multiple myeloma.

PubMed Disclaimer

References

    1. Instituto Nacional do Câncer (2012). ABC do câncer: abordagens básicas para o controle do câncer. Rev e Atual 1:1–134
    1. Devita JR VT, Lawrence TL, Rosenberg SA (2011). DeVita, Hellman and Rosenberg's cancer: principles and practice of oncology. Philadelphia: Lippincott Williams & Wilkins 9:1–384
    1. Cohen EP, Krzesinski JM, Launay-Vacher V (2015) Onco-nephrology: core curriculum 2015. Am J Kidney Dis 66:869–883 - PubMed - PMC - DOI
    1. Arellano J, Hernandez RK, Wade SW (2015) Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States. Cancer Med 4:713–720 - PubMed - PMC - DOI
    1. Lahoti A, Kantarjian H, Slahudeen AK et al (2010) Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer 116:4063–4068 - PubMed - DOI